153 related articles for article (PubMed ID: 25925927)
1. Therapy in RCDII: Rationale for Combination Strategies?
Nijeboer P; Malamut G; Bouma G; Cerf-Bensussan N; Koning F; van Bergen J; Cellier C; Mulder CJJ
Dig Dis; 2015; 33(2):227-230. PubMed ID: 25925927
[TBL] [Abstract][Full Text] [Related]
2. Identification of a potential physiological precursor of aberrant cells in refractory coeliac disease type II.
Schmitz F; Tjon JM; Lai Y; Thompson A; Kooy-Winkelaar Y; Lemmers RJ; Verspaget HW; Mearin ML; Staal FJ; Schreurs MW; Cupedo T; Langerak AW; Mulder CJ; van Bergen J; Koning F
Gut; 2013 Apr; 62(4):509-19. PubMed ID: 22760007
[TBL] [Abstract][Full Text] [Related]
3. Origin and immunophenotype of aberrant IEL in RCDII patients.
Tack GJ; van Wanrooij RL; Langerak AW; Tjon JM; von Blomberg BM; Heideman DA; van Bergen J; Koning F; Bouma G; Mulder CJ; Schreurs MW
Mol Immunol; 2012 Apr; 50(4):262-70. PubMed ID: 22364936
[TBL] [Abstract][Full Text] [Related]
4. CD4 T-cell cytokines synergize to induce proliferation of malignant and nonmalignant innate intraepithelial lymphocytes.
Kooy-Winkelaar YM; Bouwer D; Janssen GM; Thompson A; Brugman MH; Schmitz F; de Ru AH; van Gils T; Bouma G; van Rood JJ; van Veelen PA; Mearin ML; Mulder CJ; Koning F; van Bergen J
Proc Natl Acad Sci U S A; 2017 Feb; 114(6):E980-E989. PubMed ID: 28049849
[TBL] [Abstract][Full Text] [Related]
5. Dendritic cells promote expansion and survival of aberrant TCR-negative intraepithelial lymphocyte lines from refractory celiac disease type II patients.
Schmitz F; Tjon JM; van Bergen J; Koning F
Mol Immunol; 2014 Mar; 58(1):10-6. PubMed ID: 24252355
[TBL] [Abstract][Full Text] [Related]
6. The composition and differentiation potential of the duodenal intraepithelial innate lymphocyte compartment is altered in coeliac disease.
Schmitz F; Kooy-Winkelaar Y; Wiekmeijer AS; Brugman MH; Mearin ML; Mulder C; Chuva de Sousa Lopes S; Mummery CL; Staal FJ; van Bergen J; Koning F
Gut; 2016 Aug; 65(8):1269-78. PubMed ID: 25966995
[TBL] [Abstract][Full Text] [Related]
7. Single-Cell Analysis of Refractory Celiac Disease Demonstrates Inter- and Intra-Patient Aberrant Cell Heterogeneity.
Dieckman T; Schreurs M; Mahfouz A; Kooy-Winkelaar Y; Neefjes-Borst A; Bouma G; Koning F
Cell Mol Gastroenterol Hepatol; 2022; 14(1):173-192. PubMed ID: 35338007
[TBL] [Abstract][Full Text] [Related]
8. Refractory celiac disease and EATL patients show severe malnutrition and malabsorption at diagnosis.
Wierdsma NJ; Nijeboer P; de van der Schueren MA; Berkenpas M; van Bodegraven AA; Mulder CJ
Clin Nutr; 2016 Jun; 35(3):685-91. PubMed ID: 25979847
[TBL] [Abstract][Full Text] [Related]
9. Update on the Pathogenesis of Enteropathy-Associated T-Cell Lymphoma.
Abdullah SAA; Goa P; Vandenberghe E; Flavin R
Diagnostics (Basel); 2023 Aug; 13(16):. PubMed ID: 37627888
[TBL] [Abstract][Full Text] [Related]
10. Oncogenetic landscape of lymphomagenesis in coeliac disease.
Cording S; Lhermitte L; Malamut G; Berrabah S; Trinquand A; Guegan N; Villarese P; Kaltenbach S; Meresse B; Khater S; Dussiot M; Bras M; Cheminant M; Tesson B; Bole-Feysot C; Bruneau J; Molina TJ; Sibon D; Macintyre E; Hermine O; Cellier C; Asnafi V; Cerf-Bensussan N;
Gut; 2022 Mar; 71(3):497-508. PubMed ID: 33579790
[TBL] [Abstract][Full Text] [Related]
11. NKp46 is a diagnostic biomarker and may be a therapeutic target in gastrointestinal T-cell lymphoproliferative diseases: a CELAC study.
Cheminant M; Bruneau J; Malamut G; Sibon D; Guegan N; van Gils T; Cording S; Trinquand A; Verkarre V; Lhermitte L; Brousse N; Jannot AS; Khater S; Frenzel L; Delarue R; Suarez F; Marçais A; Mulder CJ; Macintyre E; Asnafi V; Pouyet L; Bonnafous C; Lhospice F; Molina TJ; Meresse B; Cellier C; Cerf-Bensussan N; Hermine O;
Gut; 2019 Aug; 68(8):1396-1405. PubMed ID: 30448772
[TBL] [Abstract][Full Text] [Related]
12. The presence of small intestinal intraepithelial gamma/delta T-lymphocytes is inversely correlated with lymphoma development in refractory celiac disease.
Verbeek WH; von Blomberg BM; Scholten PE; Kuik DJ; Mulder CJ; Schreurs MW
Am J Gastroenterol; 2008 Dec; 103(12):3152-8. PubMed ID: 19086962
[TBL] [Abstract][Full Text] [Related]
13. Recognising and Managing Refractory Coeliac Disease: A Tertiary Centre Experience.
Nasr I; Nasr I; Beyers C; Chang F; Donnelly S; Ciclitira PJ
Nutrients; 2015 Dec; 7(12):9896-907. PubMed ID: 26633478
[TBL] [Abstract][Full Text] [Related]
14. Monitoring nonresponsive patients who have celiac disease.
Krauss N; Schuppan D
Gastrointest Endosc Clin N Am; 2006 Apr; 16(2):317-27. PubMed ID: 16644460
[TBL] [Abstract][Full Text] [Related]
15. Lymphoma development and survival in refractory coeliac disease type II: Histological response as prognostic factor.
Nijeboer P; van Wanrooij R; van Gils T; Wierdsma NJ; Tack GJ; Witte BI; Bontkes HJ; Visser O; Mulder C; Bouma G
United European Gastroenterol J; 2017 Mar; 5(2):208-217. PubMed ID: 28344788
[TBL] [Abstract][Full Text] [Related]
16. Complications of coeliac disease.
Malamut G; Cellier C
Best Pract Res Clin Gastroenterol; 2015 Jun; 29(3):451-8. PubMed ID: 26060109
[TBL] [Abstract][Full Text] [Related]
17. The Intracellular Intensity of CD3 on Aberrant Intraepithelial Lymphocytes Is a Prognostic Factor of the Progression to Overt Lymphoma in Refractory Celiac Disease Type II (Pre-Enteropathy-Associated T Cell Lymphoma).
García-Hoz C; Crespo L; Lopez N; De Andrés A; Ríos León R; Santón A; Garriga M; Butz E; León F; Roy Ariño G
Dig Dis; 2020; 38(6):490-499. PubMed ID: 32015237
[TBL] [Abstract][Full Text] [Related]
18. Refractory sprue, coeliac disease, and enteropathy-associated T-cell lymphoma. French Coeliac Disease Study Group.
Cellier C; Delabesse E; Helmer C; Patey N; Matuchansky C; Jabri B; Macintyre E; Cerf-Bensussan N; Brousse N
Lancet; 2000 Jul; 356(9225):203-8. PubMed ID: 10963198
[TBL] [Abstract][Full Text] [Related]
19. Refractory Celiac Disease.
Malamut G; Cellier C
Gastroenterol Clin North Am; 2019 Mar; 48(1):137-144. PubMed ID: 30711206
[TBL] [Abstract][Full Text] [Related]
20. IL-15 triggers an antiapoptotic pathway in human intraepithelial lymphocytes that is a potential new target in celiac disease-associated inflammation and lymphomagenesis.
Malamut G; El Machhour R; Montcuquet N; Martin-Lannerée S; Dusanter-Fourt I; Verkarre V; Mention JJ; Rahmi G; Kiyono H; Butz EA; Brousse N; Cellier C; Cerf-Bensussan N; Meresse B
J Clin Invest; 2010 Jun; 120(6):2131-43. PubMed ID: 20440074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
